EISAI CO

The EMA recommended lecanemab for early Alzheimer’s, focusing on patients less likely to experience ARIA side effects. If approved, it would be the first disease-modifying therapy in the EU. The drug showed modest cognitive decline slowing in early AD patients with one or no ApoE4 gene copy. Safety measures include MRI scans and a controlled access program. The UK’s NICE questioned the drug’s cost-effectiveness, while the Alzheimer Society of Ireland highlighted the need for broader support services.

Accelerated approval, despite recent controversies, has historically provided therapeutic momentum, particularly in HIV and cancer treatments. Key issues include reliance on surrogate endpoints and confirmatory trial failures, yet the pathway has led to significant drug approvals, offering hope for diseases with high unmet needs.

Life sciences sector resilient despite challenges; significant investments in ADCs, CGTs, AI, and CDMOs. ADCs and CGTs driving growth, with China leading in clinical trials and innovation. AI transforming drug discovery and clinical trials. APAC region dominating clinical trials, especially in oncology. China's biopharma sector booming, attracting global investments. CDMOs adopting digital revolution and AI for agile manufacturing. BIOSECURE Act impacting Chinese biotech companies, benefiting Indian CDMOs.

Explore Smartkarma's AI-augmented platform with a free Preview Pass to unlock research summaries, follow top analysts, receive personalized alerts, and access analytics and events. Join 55,000+ investors, including top global asset managers. Upgrade to paid plans later.

Eisai launched Leqembi in South Korea for mild cognitive impairment due to Alzheimer’s disease or mild AD dementia. Leqembi selectively binds to amyloid-beta aggregates, reducing disease progression and cognitive decline. Developed by BioArctic and Eisai, it is approved in multiple countries and under review in others. BioArctic and Eisai are preparing for joint commercialization in the Nordic region.

The biotech sector is advancing with AI, gene editing, precision medicine, and biomanufacturing, driving drug development and treatment options. Key stocks like Amgen Inc. (AMGN), Gilead Sciences (GILD), and Biogen Inc. (BIIB) are capitalizing on these trends, focusing on oncology, neurological disorders, and infectious diseases. The global biotechnology market is expected to grow at a CAGR of 11.5% to $4.61 billion by 2033. AMGN, BIIB, and GILD are highlighted for their innovations, financial performance, and market prospects.

Eisai and Biogen launch LEQEMBI, a humanized anti-amyloid-beta monoclonal antibody, in South Korea for treating Alzheimer's disease, targeting soluble and insoluble Abeta aggregates to reduce cognitive decline.

Eisai and Biogen launch Leqembi in South Korea for mild cognitive impairment or early Alzheimer’s disease.

Eisai launches Leqembi in South Korea for mild cognitive impairment due to Alzheimer's disease. Leqembi selectively binds to amyloid-beta aggregates, reducing disease progression and cognitive decline. Developed by BioArctic and Eisai, it's the first treatment to show efficacy through this mechanism.

Eisai and Biogen launch LEQEMBI, a humanized anti-soluble aggregated amyloid-beta monoclonal antibody, in South Korea for treating mild cognitive impairment due to Alzheimer's disease or mild AD dementia. LEQEMBI selectively binds to soluble and insoluble Aβ aggregates, reducing both protofibrils and plaques in the brain, and is the first treatment shown to slow cognitive and functional decline through this mechanism.